Knock-out mouse for Canavan disease

A model for gene transfer to the central nervous system

Reuben Matalon, Peter L. Rady, Kenneth A. Platt, Henry B. Skinner, Michael J. Quast, Gerald Campbell, Kimberlee Matalon, Jeffrey D. Ceci, Stephen K. Tyring, Michael Nehls, Sankar Surendran, Jingna Wei, Ed L. Ezell, Sylvia Szucs

Research output: Contribution to journalArticle

112 Citations (Scopus)

Abstract

Background: Canavan disease (CD) is an autosomal recessive leukodystrophy characterized by deficiency of aspartoacylase (ASPA) and increased levels of N-acetylaspartic acid (NAA) in brain and body fluids, severe mental retardation and early death. Gene therapy has been attempted in a number of children with CD. The lack of an animal model has been a limiting factor in developing vectors for the treatment of CD. This paper reports the successful creation of a knock-out mouse for Canavan disease that can be used for gene transfer. Methods: Genomic library λ knock-out shuttle (λKOS) was screened and a specific pKOS/Aspa clone was isolated and used to create a plasmid with 10 base pair (bp) deletion of exon four of the murine aspa. Following linearization, the plasmid was electroporated to ES cells. Correctly targeted ES clones were identified following positive and negative selection and confirmed by Southern analysis. Chimeras were generated by injection of ES cells to blastocysts. Germ line transmission was achieved by the birth of heterozygous mice as confirmed by Southern analysis. Results: Heterozygous mice born following these experiments have no overt phenotype. The homozygous mice display neurological impairment, macrocephaly, generalized white matter disease, deficient ASPA activity and high levels of NAA in urine. Magnetic resonance imaging (MRI) and spectroscopy (MRS) of the brain of the homozygous mice show white matter changes characteristic of Canavan disease and elevated NAA levels. Conclusion: The newly created ASPA deficient mouse establishes an important animal model of Canavan disease. This model should be useful for developing gene transfer vectors to treat Canavan disease. Vectors for the central nervous system (CNS) and modulation of NAA levels in the brain should further add to the understanding of the pathophysiology of Canavan disease. Data generated from this animal model will be useful for developing strategies for gene therapy in other neurodegenerative diseases.

Original languageEnglish (US)
Pages (from-to)165-175
Number of pages11
JournalJournal of Gene Medicine
Volume2
Issue number3
StatePublished - May 2000

Fingerprint

Canavan Disease
Knockout Mice
Central Nervous System
Genes
Animal Models
Genetic Therapy
Brain
Plasmids
Clone Cells
Megalencephaly
Leukoencephalopathies
Genomic Library
Body Fluids
Blastocyst
Germ Cells
Base Pairing
Intellectual Disability
Neurodegenerative Diseases
Exons
Magnetic Resonance Spectroscopy

Keywords

  • Aspartoacylase deficiency
  • Canavan disease
  • Central nervous system model
  • Knock-out mouse
  • N-acetylaspartic acid (NAA)
  • Spongy degeneration of the brain

ASJC Scopus subject areas

  • Genetics

Cite this

Matalon, R., Rady, P. L., Platt, K. A., Skinner, H. B., Quast, M. J., Campbell, G., ... Szucs, S. (2000). Knock-out mouse for Canavan disease: A model for gene transfer to the central nervous system. Journal of Gene Medicine, 2(3), 165-175.

Knock-out mouse for Canavan disease : A model for gene transfer to the central nervous system. / Matalon, Reuben; Rady, Peter L.; Platt, Kenneth A.; Skinner, Henry B.; Quast, Michael J.; Campbell, Gerald; Matalon, Kimberlee; Ceci, Jeffrey D.; Tyring, Stephen K.; Nehls, Michael; Surendran, Sankar; Wei, Jingna; Ezell, Ed L.; Szucs, Sylvia.

In: Journal of Gene Medicine, Vol. 2, No. 3, 05.2000, p. 165-175.

Research output: Contribution to journalArticle

Matalon, R, Rady, PL, Platt, KA, Skinner, HB, Quast, MJ, Campbell, G, Matalon, K, Ceci, JD, Tyring, SK, Nehls, M, Surendran, S, Wei, J, Ezell, EL & Szucs, S 2000, 'Knock-out mouse for Canavan disease: A model for gene transfer to the central nervous system', Journal of Gene Medicine, vol. 2, no. 3, pp. 165-175.
Matalon, Reuben ; Rady, Peter L. ; Platt, Kenneth A. ; Skinner, Henry B. ; Quast, Michael J. ; Campbell, Gerald ; Matalon, Kimberlee ; Ceci, Jeffrey D. ; Tyring, Stephen K. ; Nehls, Michael ; Surendran, Sankar ; Wei, Jingna ; Ezell, Ed L. ; Szucs, Sylvia. / Knock-out mouse for Canavan disease : A model for gene transfer to the central nervous system. In: Journal of Gene Medicine. 2000 ; Vol. 2, No. 3. pp. 165-175.
@article{372e80a1f2a74717b502e4c1c4160cf2,
title = "Knock-out mouse for Canavan disease: A model for gene transfer to the central nervous system",
abstract = "Background: Canavan disease (CD) is an autosomal recessive leukodystrophy characterized by deficiency of aspartoacylase (ASPA) and increased levels of N-acetylaspartic acid (NAA) in brain and body fluids, severe mental retardation and early death. Gene therapy has been attempted in a number of children with CD. The lack of an animal model has been a limiting factor in developing vectors for the treatment of CD. This paper reports the successful creation of a knock-out mouse for Canavan disease that can be used for gene transfer. Methods: Genomic library λ knock-out shuttle (λKOS) was screened and a specific pKOS/Aspa clone was isolated and used to create a plasmid with 10 base pair (bp) deletion of exon four of the murine aspa. Following linearization, the plasmid was electroporated to ES cells. Correctly targeted ES clones were identified following positive and negative selection and confirmed by Southern analysis. Chimeras were generated by injection of ES cells to blastocysts. Germ line transmission was achieved by the birth of heterozygous mice as confirmed by Southern analysis. Results: Heterozygous mice born following these experiments have no overt phenotype. The homozygous mice display neurological impairment, macrocephaly, generalized white matter disease, deficient ASPA activity and high levels of NAA in urine. Magnetic resonance imaging (MRI) and spectroscopy (MRS) of the brain of the homozygous mice show white matter changes characteristic of Canavan disease and elevated NAA levels. Conclusion: The newly created ASPA deficient mouse establishes an important animal model of Canavan disease. This model should be useful for developing gene transfer vectors to treat Canavan disease. Vectors for the central nervous system (CNS) and modulation of NAA levels in the brain should further add to the understanding of the pathophysiology of Canavan disease. Data generated from this animal model will be useful for developing strategies for gene therapy in other neurodegenerative diseases.",
keywords = "Aspartoacylase deficiency, Canavan disease, Central nervous system model, Knock-out mouse, N-acetylaspartic acid (NAA), Spongy degeneration of the brain",
author = "Reuben Matalon and Rady, {Peter L.} and Platt, {Kenneth A.} and Skinner, {Henry B.} and Quast, {Michael J.} and Gerald Campbell and Kimberlee Matalon and Ceci, {Jeffrey D.} and Tyring, {Stephen K.} and Michael Nehls and Sankar Surendran and Jingna Wei and Ezell, {Ed L.} and Sylvia Szucs",
year = "2000",
month = "5",
language = "English (US)",
volume = "2",
pages = "165--175",
journal = "Journal of Gene Medicine",
issn = "1099-498X",
publisher = "John Wiley and Sons Ltd",
number = "3",

}

TY - JOUR

T1 - Knock-out mouse for Canavan disease

T2 - A model for gene transfer to the central nervous system

AU - Matalon, Reuben

AU - Rady, Peter L.

AU - Platt, Kenneth A.

AU - Skinner, Henry B.

AU - Quast, Michael J.

AU - Campbell, Gerald

AU - Matalon, Kimberlee

AU - Ceci, Jeffrey D.

AU - Tyring, Stephen K.

AU - Nehls, Michael

AU - Surendran, Sankar

AU - Wei, Jingna

AU - Ezell, Ed L.

AU - Szucs, Sylvia

PY - 2000/5

Y1 - 2000/5

N2 - Background: Canavan disease (CD) is an autosomal recessive leukodystrophy characterized by deficiency of aspartoacylase (ASPA) and increased levels of N-acetylaspartic acid (NAA) in brain and body fluids, severe mental retardation and early death. Gene therapy has been attempted in a number of children with CD. The lack of an animal model has been a limiting factor in developing vectors for the treatment of CD. This paper reports the successful creation of a knock-out mouse for Canavan disease that can be used for gene transfer. Methods: Genomic library λ knock-out shuttle (λKOS) was screened and a specific pKOS/Aspa clone was isolated and used to create a plasmid with 10 base pair (bp) deletion of exon four of the murine aspa. Following linearization, the plasmid was electroporated to ES cells. Correctly targeted ES clones were identified following positive and negative selection and confirmed by Southern analysis. Chimeras were generated by injection of ES cells to blastocysts. Germ line transmission was achieved by the birth of heterozygous mice as confirmed by Southern analysis. Results: Heterozygous mice born following these experiments have no overt phenotype. The homozygous mice display neurological impairment, macrocephaly, generalized white matter disease, deficient ASPA activity and high levels of NAA in urine. Magnetic resonance imaging (MRI) and spectroscopy (MRS) of the brain of the homozygous mice show white matter changes characteristic of Canavan disease and elevated NAA levels. Conclusion: The newly created ASPA deficient mouse establishes an important animal model of Canavan disease. This model should be useful for developing gene transfer vectors to treat Canavan disease. Vectors for the central nervous system (CNS) and modulation of NAA levels in the brain should further add to the understanding of the pathophysiology of Canavan disease. Data generated from this animal model will be useful for developing strategies for gene therapy in other neurodegenerative diseases.

AB - Background: Canavan disease (CD) is an autosomal recessive leukodystrophy characterized by deficiency of aspartoacylase (ASPA) and increased levels of N-acetylaspartic acid (NAA) in brain and body fluids, severe mental retardation and early death. Gene therapy has been attempted in a number of children with CD. The lack of an animal model has been a limiting factor in developing vectors for the treatment of CD. This paper reports the successful creation of a knock-out mouse for Canavan disease that can be used for gene transfer. Methods: Genomic library λ knock-out shuttle (λKOS) was screened and a specific pKOS/Aspa clone was isolated and used to create a plasmid with 10 base pair (bp) deletion of exon four of the murine aspa. Following linearization, the plasmid was electroporated to ES cells. Correctly targeted ES clones were identified following positive and negative selection and confirmed by Southern analysis. Chimeras were generated by injection of ES cells to blastocysts. Germ line transmission was achieved by the birth of heterozygous mice as confirmed by Southern analysis. Results: Heterozygous mice born following these experiments have no overt phenotype. The homozygous mice display neurological impairment, macrocephaly, generalized white matter disease, deficient ASPA activity and high levels of NAA in urine. Magnetic resonance imaging (MRI) and spectroscopy (MRS) of the brain of the homozygous mice show white matter changes characteristic of Canavan disease and elevated NAA levels. Conclusion: The newly created ASPA deficient mouse establishes an important animal model of Canavan disease. This model should be useful for developing gene transfer vectors to treat Canavan disease. Vectors for the central nervous system (CNS) and modulation of NAA levels in the brain should further add to the understanding of the pathophysiology of Canavan disease. Data generated from this animal model will be useful for developing strategies for gene therapy in other neurodegenerative diseases.

KW - Aspartoacylase deficiency

KW - Canavan disease

KW - Central nervous system model

KW - Knock-out mouse

KW - N-acetylaspartic acid (NAA)

KW - Spongy degeneration of the brain

UR - http://www.scopus.com/inward/record.url?scp=0034182887&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034182887&partnerID=8YFLogxK

M3 - Article

VL - 2

SP - 165

EP - 175

JO - Journal of Gene Medicine

JF - Journal of Gene Medicine

SN - 1099-498X

IS - 3

ER -